Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HeLa-FLCN KO upon Trametinib treatment [Trametinib_RNAseq]

ABSTRACT: HeLa-FLCN KO upon Trametinib treatment [Trametinib_RNAseq]

PROVIDER: PRJNA862893 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20670901.fastq.gz	Fastqsanger.gz
	SRR20670887.fastq.gz	Fastqsanger.gz
	SRR20670889.fastq.gz	Fastqsanger.gz
	SRR20670891.fastq.gz	Fastqsanger.gz
	SRR20670893.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

HeLa-FLCN KO upon Trametinib treatment [Trametinib_RNAseq]

Project description:Transcriptional regulation of gene expression plays a fundamental role in coordinating molecular and metabolic responses to stress conditions. The stress-responsive Transcription Factor EB (TFEB), the master controller of lysosomal biogenesis and autophagy, is regulated at the post-translational level by the nutrient-sensitive kinase complex TORC1. However, little is known about the transcriptional regulation of TFEB in physiological and pathological conditions. Here, we show that during starvation, the immediate-early gene EGR1 binds to the TFEB promoter and positively regulates TFEB expression. EGR1 depletion dampened TFEB-mediated transcriptional response to starvation and significantly inhibited cell proliferation in cellular and 3D spheroid models of Birt-Hogg-Dube' (BHD) syndrome, a TFEB-driven inherited cancer condition. Consistently, the MEK1/2 inhibitor Trametinib, known to inhibit EGR1 expression, suppressed the proliferation of BHD patient-derived cancer cells, suggesting that pharmacological inhibition of the EGR1-TFEB axis may represent a therapeutic strategy to counteract constitutive TFEB activation in cancer-associated conditions.

2023-02-12 | GSE209898 | GEO

The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue

Project description:differential display between WT and FLCN KO

2016-11-11 | GSE89762 | GEO

Phosphoproteomic analysis of the Folliculin (FLCN) tumor suppressor reveals FLCN-dependent kinase signaling and TFEB regulation

Project description:In Birt-Hogg-Dubé (BHD) syndrome, germline mutations in the Folliculin (FLCN) gene lead to an increased risk of renal cancer. To address if FLCN is involved regulating cellular signaling pathways via protein and receptor phosphorylation we determined comprehensive complete phosphoproteomic profiles of FLCNPOS and FLCNNEG human renal tubular epithelial cells (RPTEC/TERT1). In total, 15744 phosphorylated peptides were identified, residing on 4329 phosphorylated proteins. Kinase activity inference analysis revealed that FLCN loss elevates phosphorylation of numerous kinases, including tyrosine kinases EPHA2 and MET, as well as activation of downstream MAPK1/3/6 and 8. Three non-canonical phosphorylation sites on EGFR (Tyr1125, Tyr1138 and Tyr1172) were higher phosphorylated upon FLCN loss together with enhanced phosphorylated EGFR substrates ABI, EPS8, ERRFL1, STAT1, PTK2 and CTNND1. In concordance, phosphosite specific signature analyses revealed an enrichment for EGFR signaling in FLCNNEG cells. Interestingly, we detected FLCN dependent phosphorylation of PIK3CD but no canonical downstream Akt/mTOR activation. In agreement with the induction of the E-box transcriptional gene expression signature upon FLCN loss, here we identified that phosphorylation of TFEB on Ser109, Ser114 and Ser122 is dependent on FLCN and absence of this phosphorylation results in constitutive nuclear localization of this transcription factor in FLCNNEG cells. Together, our study reveals enhanced phosphorylation of specific kinases and substrates in FLCNNEG renal epithelial cells, providing important insights in BHD-associated renal tumorigenesis and offering novel handles for the design of targeted therapies.

2022-07-11 | PXD025798 | Pride

Gene expression data from FLCN-restored UOK257-2 renal cancer cells

Project description:UOK257 cell line was derived from a BHD patient. It harbors a germline mutation in FLCN (c.1285dupC) and LOH. UOK257-2 cells were generated from UOK257 cells by introducing wildtype FLCN using retrovirus. FLCN inactivation induces TFE3 transcriptional activity by increasing its nuclear localization. Thus expression microarray was used to identify the genes regulated by FLCN and TFE3. UOK257-2 cells expressing wildtype FLCN were transfected with 1) scrambled, 2) FLCN, 3) TFE3 and 4)FLCN/TFE3 siRNAs with Lipofectamine 2000 transfection reagent. Cells were harvested 3 days after transfection and RNAs were isolated using Trizol reagent and RNeasy Mini Kit. The genes induced by FLCN siRNA and reduced by TFE3 siRNA were chosen as a candidate genes regulated by FLCN and TFE3.

2010-10-11 | E-GEOD-23614 | biostudies-arrayexpress

ADAR1-editing in HeLa, p150-KO and ADAR1-KO transcriptomes

Project description:ADAR1-editing in HeLa, p150-KO and ADAR1-KO transcriptomes

| PRJNA473839 | ENA

Microarray upon ZMYND8 knockdown in Hela cells

Project description:Microarray upon ZMYND8 knockdown in Hela cells

| PRJNA418410 | ENA

RNA-seq analysis of HeLa METTL5-KO cells compared to WT HeLa cells

Project description:To identify transcripts upregulated and downregulated upon METTL5 knockout in HeLa cells.

2021-05-17 | GSE174503 | GEO

Flcn and BHD renal tumorigenesis

Project description:Targeted disruption of Flcn in mouse kidney proximal tubule gives insights into human BHD renal tumorigenesis Mouse Tumor kidney tissue vs. normal kidney tissue

2014-07-28 | E-GEOD-49397 | biostudies-arrayexpress

Gene expression data from FLCN-restored UOK257-2 renal cancer cells

2010-10-11 | GSE23614 | GEO

Flcn and BHD renal tumorigenesis

Project description:Targeted disruption of Flcn in mouse kidney proximal tubule gives insights into human BHD renal tumorigenesis

2014-07-28 | GSE49397 | GEO